Stomach Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Also, eIF2α-P stimulation by the phosphatase inhibitor SAL003 substantially increases Trastuzumab potency in resistant HER2+ breast and gastric tumors.
|
31086176 |
2019 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
|
30365359 |
2019 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
However, the cellular distribution of HER2 protein in gastric tumors is dynamic, and HER2 internalization decreases antibody binding to tumor cells.
|
31171598 |
2019 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Thus, this study evaluated the tumor regression grading (TRG) in a series of post-treatment gastric tumors and its associations with HER2, MET, and FOXP3 expression.
|
29696715 |
2018 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
HER2-positivity was significantly higher in males (16.1% vs. 9.6% in females), in gastroesophageal versus stomach tumors (22.1% vs. 12.9%), in biopsy versus surgical samples (18.3% vs. 13.0%), in intestinal tumor subtypes versus diffuse (21.5% vs. 4.8%) and mixed types (21.5% vs. 8.5%) (P<0.001), in mixed versus diffuse types (8.5% vs. 4.8%), and in "other" versus diffuse types (11.7% vs. 4.8%; P=0.002).
|
27490762 |
2018 |
Stomach Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
This study demonstrated a significant difference in the overexpression of HER2/neu in gastric tumors.
|
25292034 |
2014 |
Stomach Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
HER2/neu overexpression (IHC 3+) was detected in 19% (10 of 54) of gastric tumors, and overall correlation between manual HER2/neu IHC interpretation and IA interpretation was 78% (42 of 54).
|
22646266 |
2012 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
CTD_human |
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
|
22042947 |
2011 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
CTD_human |
Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
|
21532492 |
2011 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Despite advances with traditional single genes molecular research, including rare mutations in BRCA1/2 and CDH1 for primary prevention and trastuzumab for treating HER2-overexpressing breast and gastric tumors, overall, treatment failure and death rates are still alarmingly high.
|
20975737 |
2011 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
LHGDN |
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.
|
19156142 |
2009 |
Stomach Neoplasms
|
0.700 |
AlteredExpression
|
group |
LHGDN |
Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
|
18483367 |
2008 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
LHGDN |
HER-2/neu amplification is an independent prognostic factor in gastric cancer.
|
16868827 |
2006 |
Stomach Neoplasms
|
0.700 |
AlteredExpression
|
group |
LHGDN |
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
|
16733844 |
2006 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
LHGDN |
Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas.
|
16457151 |
2006 |
Stomach Neoplasms
|
0.700 |
AlteredExpression
|
group |
LHGDN |
Membranous levels of c-erbB-2 oncoprotein in gastric cancer: their relationship with clinicopathological parameters and their prognostic significance.
|
15646832 |
2005 |
Stomach Neoplasms
|
0.700 |
AlteredExpression
|
group |
LHGDN |
Coamplified and overexpressed genes at ERBB2 locus in gastric cancer.
|
14991576 |
2004 |
Stomach Neoplasms
|
0.700 |
Biomarker
|
group |
CTD_human |
Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy.
|
15640503 |
2004 |
Stomach Neoplasms
|
0.700 |
GeneticVariation
|
group |
LHGDN |
A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer.
|
14520697 |
2003 |
Stomach Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Thus, overexpression of normal size erbB-2 mRNA accompanies gene amplification in primary stomach tumors.
|
2573419 |
1989 |
Stomach Neoplasms
|
0.700 |
CausalMutation
|
group |
CGI |
|
|
|
Stomach Neoplasms
|
0.700 |
GenomicAlterations
|
group |
CGI |
|
|
|
Stomach Neoplasms
|
0.700 |
CausalMutation
|
group |
CLINVAR |
|
|
|